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tNTRODUCTION
Improvements in supportive care and the use of
eripheral blood stem cells have increased the safety
f autologous transplantation, making it an effective
herapy for more patients with hematologic malignan-
ies and some solid tumors. Although more patients,
ncluding older patients, are successfully undergoing
ransplantation, the major obstacle to long-term suc-
ess remains relapse. In addition to relapse, there are
ome unresolved questions concerning the optimal
iming of transplantation (ﬁrst remission versus re-
apse) and the type of regimen (radiation based or
hemotherapy based). Although short- and long-term
omplications are less common after autologous trans-
lantation compared with allogeneic transplantation,
yelodysplasia remains a unique and troublesome late
ffect, particularly for patients with lymphoma and
odgkin lymphoma [1-3]. This session will focus on
he current status of autologous stem cell transplan-
ation for hematologic malignancy, with emphasis on
trategies being explored to help reduce the chances of
elapse, the major impediment to long-term survival
or patients undergoing treatment.
ON-HODGKIN LYMPHOMA
The initial report of successful high-dose therapy
n transplantation in 1978 from the National Cancer
nstitute in patients with very advanced disease was
ollowed by reports from Philip et al. [4,5] of a cure
ate of 35% to 40% in patients with relapsed chemo-
ensitive diffuse aggressive lymphoma. These results
ere conﬁrmed in 1995 with a multinational PARMA
rial in which patients were randomized to receive
econd-line chemotherapy with cisplatinum, cytosine d
8rabinoside, and dexamethasone with radiotherapy or
he same regimen combined with high-dose BCNU,
toposide, ara-C, and cyclophosphamide. The 5-year
vent-free survival was 46% for transplanted patients
ersus 12% for chemotherapy-only patients [5]. After
his, many studies, including single-institutions and
ooperative groups, have shown that approximately
0% of patients with relapsed large cell lymphomas
hat are sensitive to chemotherapy can be cured [6-9].
his ﬁgure does not include patients who do not
chieve a remission with initial treatment or who are
efractory to chemotherapy, thus leaving considerable
oom for improvement in all groups of patients. In-
ovations in transplantation for lymphoma have fo-
used on more effective transplantation regimens,
obilization and collection of stem cells free of
ontamination by tumor cells, and, more recently,
he development of immunotherapy as a component
f the treatment.
Theoretically, a larger proportion of patients will
ave relative, rather than absolute, drug resistance
arlier in the course of their disease; thus, trials were
onducted with high-dose therapy in poor-risk pa-
ients during their ﬁrst response or remission [10-12].
ubsequently, this concept has been tested in multiple
linical trials that differ in patient selection, patho-
ogic subtype, choice and extent of induction therapy,
ime and selection for randomization, and statistical
ower to observe treatment effects. Thus, several tri-
ls have reported a beneﬁt where others have not
13,14]. In general, patients with poor prognostic fea-
ures at the time of diagnosis have been those for
hom these trials have shown beneﬁt. Recently, re-
ults have been reported in adult patients with un-
reated aggressive lymphoma with a low, low-interme-
iate, and high-intermediate risk of death according to
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Bn age-adjusted international prognostic index and
ho then received treatment with cyclophosphamide,
ydroxydaunomycin, Oncovin [vincristine], and pred-
isone [CHOP] followed by either observation or
utologous stem cell transplantation after high-dose
hemotherapy [15]. The estimated event-free survival
t 5 years was signiﬁcantly higher among patients who
eceived high-dose therapy than among those who
eceived CHOP (55% versus 37%; P  .037). Among
atients with a high-intermediate risk of death, ac-
ording to the age-adjusted international prognostic
ndex, the 5-year survival rate was signiﬁcantly higher
fter high-dose therapy than after CHOP (74% versus
4%; P  .001). This trial, although optimistic and
onsistent with other reports, did not include ritux-
mab as part of the transplantation regimen or, more
mportantly, as part of the chemotherapy, and this
ay have affected the results. In addition, changes in
he initial treatment of large-cell lymphoma, including
he use of anti-CD20 antibody and a shortened inter-
al between cycles of CHOP, can affect the control
rm of the study, thus making such trials limited by
he control arm [16,17]. Currently, US cooperative
roups are testing the hypothesis that high-interme-
iate–risk and high-risk patients who respond to a full
ourse of CHOP would beneﬁt from early autologous
ransplantation versus autologous transplantation at
elapse, and they include anti-CD20 antibody as part
f the treatment program.
To address the major problem of relapse, investi-
ators have explored means of augmenting the dose of
ntineoplastic therapy delivered to the tumor. This
ncludes the addition of etoposide to the standard
egimen of total body irradiation and cyclophospha-
ide, and excellent results have been obtained in the
ooperative group setting. Press et al. [18] pioneered
he use of high-dose radioimmunotherapy in conjunc-
ion with autologous hematopoietic cell transplanta-
ion. After demonstration of the safety and efﬁcacy of
odine 131 linked to the anti-CD20 antibody tositu-
omab, the radioimmunoconjugate was combined
ith Etoposide and Cyclophosphamide followed by
utologous transplantation and seemed more effective
han the historical control. Subsequently, Vose et al.
19] safely escalated iodine 131–tositumomab with
ull-dose BCNU, etoposide, cytosine, arabinoside,
elphalan (BEAM) before transplantation. More re-
ently, Nademanee et al. [20] successfully escalated
ttrium 90 chelated with ibritumomab, a murine anti-
D20 antibody, in combination with Etoposide and
yclophosphamide, with excellent results and good
olerance. These studies suggest that targeted radia-
ion may be more effective and better tolerated than
ull total body radiation or non–total body irradia-
ion–based regimens. Antibody targeting has also led
o the exploration of T cells genetically modiﬁed with
n antibody-based immunoreceptor to recognize the t
B & M TD19 or CD20 antigen on lymphoma cells (see be-
ow) [21].
Although most studies have focused on the use of
utologous stem cell transplantation for large cell lym-
homa, studies on the other subtypes of lymphoma,
articularly mantle cell and indolent lymphoma, have
lso been conducted. The recognition of a different
linical biology of this disease has led to different and,
n some ways, more intensive approaches, including
he use of cyclophosphamide, hydroxydaunomycin,
incristine, dexamethasone, methotrexate, cytosine ar-
binoside (hyperCVAD) for induction therapy and the
arly use of autologous transplantation for mantle cell
ymphoma. The data suggest that, for mantle cell
ymphoma, autologous stem cell transplantation in
rst remission is associated with improved outcome,
hereas patients who undergo transplantation after
rst remission rarely beneﬁt by such an approach and
re more often candidates for allogeneic transplanta-
ion [22,23]. For patients with relapsed low-grade
ymphoma, a comparative clinical trial of autologous
ransplantation versus reduced-intensity allogeneic
ransplantation is being conducted by the Transplant
linical Trials Network.
ULTIPLE MYELOMA
The improvements in supportive care and the devel-
pment of speciﬁc regimens for myeloma have expanded
he therapeutic potential in a disease that is more com-
only seen in older patients. Although not curative in
ost patients, autologous stem cell transplantation im-
roves the likelihood of a complete response and of
rolonged disease-free survival and overall survival, and
t is a major advance in myeloma treatment [24]. Most
rials have indicated that prognosis is determined accord-
ng to whether patients are able to achieve a complete
esponse. The most commonly used treatment regimen
s melphalan at 200 mg/m2 given on either 1 or 2 days,
nd this has replaced other regimens, particularly those
hat combine chemotherapy with radiation. Some con-
roversy remains about the overall role of autologous
tem cell transplantation, particularly in patients already
esponding to therapy, and whether it needs to be per-
ormed as part of the up-front treatment or whether it
an be delayed until patients show evidence of disease
rogression [25].
On the basis of these observations and the lack of
survival plateau in patients undergoing autologous
tem cell transplantation, tandem autologous trans-
lantation was developed to improve complete re-
ponse rates. In a randomized trial conducted in
rance, event-free survival and overall survival were
igniﬁcantly better among recipients of tandem trans-
lants than among those who underwent a single au-
ologous stem cell transplantation, particularly for pa-
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3ients not in remission after the ﬁrst cycle [26].
owever, preliminary data from other randomized
rials have not shown a convincing improvement in
verall survival among patients undergoing tandem
ransplantation, although the follow-up is too short to
ake any deﬁnitive conclusions [27].
Similar to regimens for lymphoma, alternative
egimens are being developed to improve the antitu-
or response. These include the use of bone-seeking
adioactive holmium and samarium [28]. In addition,
n increasing number of new medications are being
eveloped for myeloma that will likely change not
nly the treatment for relapse, but also the up-front
reatment, including the use of lcnalidomide and bort-
zomib [29,30]. Given that the patient’s disease bur-
en at the time of transplantation affects disease-free
urvival, it is likely that an improved up-front treat-
ent will also affect transplant results.
Allogeneic transplantation is also re-emerging as
n option for patients with multiple myeloma; it is
ased on the facts that the graft is not contaminated
ith tumor cells and that the graft-versus-myeloma
ffect has been demonstrated [31]. This, combined
ith new approaches to performing allogeneic trans-
lantation by using immunosuppressive medications
o facilitate engraftment, is allowing successful trans-
lantation in older patients [32]. Currently, a trial
esigned by the Transplant Clinical Trials Network at
he National Institutes of Health comparing autolo-
ous transplantation followed by either a second au-
ologous transplantation or a mini–allogeneic trans-
lantation is being performed. One novel aspect of
his trial is the use of post–tandem autologous trans-
lantation treatment to address minimal residual dis-
ase with dexamethasone and thalidomide and may
erve as a model for future innovations.
ODGKIN LYMPHOMA
With increasing innovations in the use of up-front
hemotherapy and radiation therapy, the vast majority of
atients with Hodgkin disease can be cured with initial
herapy. Thus, transplantation studies in Hodgkin lym-
homa have been conducted in patients who either do
ot achieve a complete remission or who relapse after
chieving 1 or more remissions [33,34]. The most com-
on regimens have been the combination of Cyclophos-
hamide, BCNU and VP-16, BEAM, and total body
rradiation–based regimens. A large number of variables
ssociated with the outcome of autologous transplanta-
ion have been identiﬁed, including (1) bulky or minimal
isease after transplantation, (2) the amount of therapy
efore transplantation, (3) performance status, (4) dura-
ion of initial remission, (5) extranodal disease at relapse,
6) systemic symptoms at relapse, (7) chemotherapy re-
istance, (8) age, (9) stage at relapse, (10) progressive t
0isease at relapse, and (11) lactic dehydrogenase level at
ransplantation [35,36]. On the basis of these consider-
tions, attempts have been made to understand treat-
ent results according to patient characteristics at trans-
lantation. Such analyses reveal actuarial survivals that
ary from as high as 80% to as low as 15%. Most studies
how that extensive therapy before transplantation, poor
erformance status, chemotherapy resistance, and active
isease at the time of transplantation are predictive of a
oor outcome after autologous transplantation [37,38].
An important issue in autologous transplantation
or Hodgkin disease is the appropriate timing of trans-
lantation during the course of the disease. Although
ome patients who have an isolated lymph node re-
urrence and a long initial progression-free survival
an be treated with either chemotherapy or involved-
eld radiation, patients who do not attain an initial
omplete remission or who have a short ﬁrst remission
fter combination chemotherapy and second or sub-
equent relapse are very appropriate candidates for
his treatment. In each of these situations, data sup-
ort the use of autologous transplantation to prevent
elapse [39].
There are considerably fewer data to evaluate or
upport autologous stem cell transplantation for pa-
ients with high-risk disease during ﬁrst complete re-
ission. These single-center reports, which are fo-
used on patients who had poor prognostic signs at the
ime of diagnosis and who had responded to therapy,
how very good survival, but comparative trials are
acking [40,41]. To improve outcome, pilot trials have
een performed to determine the potential efﬁcacy of
andem autologous transplantation in patients with
dvanced poor-risk Hodgkin lymphoma [42,43]. In
ne study of a group of 49 patients with refractory
isease who had either primary induction failure or a
hort remission, tandem autologous transplantation
esulted in a 3-year event-free survival of 50% [43].
he concept will be tested in a phase II Southwest
ncology Group study to determine its overall effect,
articularly in poor-risk patients.
The therapeutic options for patients with relapsed
odgkin lymphoma have not changed signiﬁcantly
ver the past decade, and, in contrast to Hodgkin
ymphoma, no immunotherapeutic approach has been
eveloped that has proven to be effective. The CD30
ntigen was deﬁned by the monoclonal antibody Ki1
n 1982 and as a structural protein in the membrane of
odgkin lymphoma in 1985 [44]. It is expressed at
nly very low levels in T and B cells but is consistently
xpressed in Reed-Sternberg cells found in Hodgkin
ymphoma and in lymphoma cells of patients with
naplastic large cell lymphoma, T-cell type. The pres-
nce of CD30 on Reed-Sternberg cells makes it an
ttractive target for immune-mediated therapy using
D30 antibodies, immunotoxins, and radioimmuno-
herapy.
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BCUTE MYELOGENOUS LEUKEMIA
Interest in autologous transplantation has in-
reased substantially, in part by the limited success of
tandard-dose chemotherapy in achieving long-term,
isease-free survival for the vast majority of patients
ith acute myelogenous leukemia (AML). The results
f trials using autologous hematopoietic cells in pa-
ients with AML in ﬁrst complete remission vary from
4% to 70% according to the patient’s age, duration
f remission before transplantation, and, most impor-
antly, cytogenetic evaluation at the time of transplan-
ation [45-47]. The role of autologous transplantation
n second remission is better deﬁned, because the cure
ate with conventional chemotherapy is extremely
ow. Trials using unpurged marrow demonstrate a
0% to 40% disease-free survival, and this is an alter-
ative for patients who lack a related or unrelated
onor [48]. For patients with acute promyelocytic
eukemia, the outcome of autologous transplantation
ith a polymerase chain reaction–negative graft is
xcellent [49]. For patients in whom polymerase chain
eaction negativity of the graft cannot be obtained,
llogeneic transplantation is the preferred therapy.
Currently, studies are ongoing to address the ma-
or problem of relapse in patients undergoing autolo-
ous transplantation. These include the exploration of
ini–allogeneic transplantation for older patients
ith AML and the inclusion of radioimmunoisotopes
s part of the preparative regimen to better target sites
f disease and improve the effect of treatment for both
utologous and allogeneic transplantation regimens
50,51]. Other investigators are exploring the use of
osttransplantation immunotherapy or immunization
o speciﬁc antigens to induce an immune response to
reat minimal residual disease [52].
Some patients with secondary AML arising out of
yelodysplasia who achieve a remission have under-
one autologous transplantation. Although some stud-
es, particularly those in Europe, have shown some
eneﬁcial results in patients, these are a highly se-
ected group of patients who achieve a remission with
hemotherapy, with negative cytogenetics and normal
lood counts, and are able to have adequate stem cells
ollected [53]. They represent a small minority of
atients who develop AML after myelodysplasia—a
opulation of patients best treated with an allogeneic
pproach.
CUTE LYMPHOBLASTIC LEUKEMIA
Development of an effective autologous transplan-
ation regimen for acute lymphoblastic leukemia
ALL) has been difﬁcult. In general, the results with
llogeneic transplantation for patients with poor-risk
isease, including those in second remission, have
ade it the preferred treatment approach [54]. A re-
B & M Tent update of the French LALA trial suggests that
llogeneic stem cell transplantation improves disease-
ree survival for high-risk ALL in ﬁrst remission and
hat autologous stem cell transplantation does not
onfer a signiﬁcant beneﬁt over chemotherapy for
igh-risk ALL [55]. This is similar to the preliminary
esult from the Eastern Cooperative Oncology
roup/Medical Research Council trial [56]. On the
asis of this result, most current trials are pilot studies
esigned to augment the efﬁcacy of the regimen by
sing radioimmunotherapy, infusion of genetically
odiﬁed T cells designed to treat minimal residual
isease, or imatinib (Gleevec; Novartis, Basel, Swit-
erland) for patients before and after transplantation
ith Philadelphia chromosome–positive ALL.
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